Amgen's Plunging Volume Reflects Mixed Biotech Sector Sentiment as Stock Ranks 163rd in Trading Activity

Amgen (AMGN) closed higher by 0.28% on Sept. 23, 2025, with a trading volume of $630 million, representing a 27.63% decline from the previous day’s volume. The stock ranked 163rd in terms of trading activity among listed equities, reflecting a mixed market sentiment toward biotech sector performers.

Recent regulatory updates surrounding oncology drug approvals have positioned Amgen as a key player in the therapeutic innovation race. Analysts noted that ongoing Phase III trial results for its experimental hematology therapy could influence short-term trading dynamics, though no immediate catalysts were identified in the near term. The biopharma giant’s R&D pipeline remains under scrutiny, particularly as competitors advance gene-editing technologies.

Investor focus has shifted to macroeconomic indicators, with rising interest rates tempering aggressive bets on high-growth biotech stocks. Amgen’s dividend yield of 0.58% currently outperforms the S&P 500 Health Care sector average, offering a defensive appeal amid market volatility. However, the stock’s muted volume suggests limited institutional participation in recent sessions.

To run this back-test robustly I need to pin down a few implementation details: 1. Universe • Which market(s) are we ranking? (e.g., all U.S. common stocks, only the S&P 500 constituents, all stocks on a specific exchange, etc.) 2. Volume definition • Do you want to rank on today’s trading-volume and buy at the next day’s open, or buy at the same day’s close after volumes are known? • Raw share volume or dollar volume? 3. Weighting scheme • Equal-weight the 500 names each day, or weight by something else (e.g., proportional to volume)? 4. Transaction costs & slippage • Should we apply any commissions or slippage assumptions, or treat trades as frictionless? 5. Benchmark / risk-free rate (if any) • Useful for excess-return and Sharpe calculations.